SCHEMBL13948871

SCHEMBL13948871

CCOC(=O)CCSc1ccccc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 3/20 0.52
POLB P06746 2/20 0.52
L3MBTL1 Q9Y468 3/20 0.48
ATM Q13315 1/20 0.48
ALDH1A1 P00352 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.47
CYP4F2 P78329 2/20 0.46
CYP4A11 Q02928 2/20 0.46
RAB9A P51151 2/20 0.46
HPGD P15428 2/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.45
GLA P06280 1/20 0.44
LMNA P02545 1/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28446155 0.84 ALDH1A1 (0.58) MAPTKMT2AKDM4EPOLBL3MBTL1
SCHEMBL15915950 0.84 POLB (0.50) MAPTKMT2AKDM4EPOLBL3MBTL1
SCHEMBL7153877 0.83 L3MBTL1 (0.60) MAPTKMT2AKDM4EPOLBL3MBTL1
SCHEMBL10382679 0.83 TSHR (0.57) MAPTKMT2AKDM4EPOLBL3MBTL1
SCHEMBL4840587 0.83 CYP4F2 (0.61) MAPTKMT2AKDM4EPOLBL3MBTL1
SCHEMBL4841613 0.83 CYP4F2 (0.50) MAPTKMT2AKDM4EPOLBL3MBTL1
SCHEMBL7423596 0.83 MTNR1A (0.56) MAPTKMT2AKDM4EPOLBL3MBTL1
SCHEMBL4842111 0.82 CYP4F2 (0.49) MAPTKMT2AKDM4EPOLBL3MBTL1
SCHEMBL7344673 0.80 ALDH1A1 (0.61) MAPTKMT2AKDM4EPOLBL3MBTL1
SCHEMBL5637483 0.80 SMN1; SMN2 (0.56) MAPTKMT2AKDM4EPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1885695-B1 INDOLINE COMPOUNDS FOURNIER LAB SA (FR) 2009-02-25 EP disclosed
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 US disclosed
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 US disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 US disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 US disclosed
WO-2007000550-A2 NOVEL INDOLINE COMPOUNDS LABORATOIRES FOURNIER S.A. (FR) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119465-A1 Novel Indoline Compounds GPR119, INSR, IRS1 MAPT 763/4885KMT2A 1435/4885KDM4E 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.